DETAILED INFORMATION ON FAVIPIRAVIR: DRUG FOR TREATMENT OF SARS-COV-2

MONAJI SANJANA REDDY

doi:10.22159/ijms.2020.v8i6.39580

Authors

MONAJI SANJANA REDDY Department of Samskruti College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.22159/ijms.2020.v8i6.39580

Keywords:

SARS-CoV-2, Favipiravir, Future hopes

Abstract

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is another name given to pandemic disease COVID-19 that is caused by a newly discovered coronavirus. People infected with coronavirus will experience mild-to-moderate respiratory illness, and it can be seen in a serious stage when comorbidities include along with it. This is now creating a huge pandemic situation all over the world with a huge rate of sufferers, that is, around 9.06 million around the world and about 440 k in India till today according to the World Health Organization. This is a serious condition that should be solved with vaccine only as coronavirus is undergoing mutation it makes difficult to invent a vaccine for it. So far, about 200 genetic mutations have been discovered across the world also in these 198 mutations appeared independently more than once. Due to this pandemic situation, there are so many clinical trials going on in discovering vaccines. Recently, after many trails conducting favipiravir are found to be the most successful in treating any stage of SARS-CoV-2. This article focuses completely on this area, along with its mechanism, side effects, uses, and contraindications.

References

Korber B, Fischer WM, Yoon H, Theiler J, Abfalterer W, Gnanakaran S,et al. Spike mutation pipeline reveals the emergence of a moretransmissible form of SARS-CoV-2. BioRxiv 2020;

Kumudhaveni B, Kathirvel S, Deepak Muthu S,Jeradsuresh A, Radha R. Potential drug candidates for treatmentof covid-19. Int J Pharm Sci Res 2017; Available from:https://www.ijpsr.com/bft-article/potential-drug-candidates-for-tre atment-of-covid-19 [Last accessed on 2020 Sep 18].

Variants, Lineages, and Strains of Coronavirus-the Startup-medium. Available from: https://www.medium.com/swlh/variants-lineages-and-strains-of-coronavirus-7a71a0e699d7. [Last accessed on 2020 Jun 23].

Available from: https://www.miro.medium.com/max/1400/1*H0nTPEvFofne4A216InfgA.jpeg. [Last accessed on 2020 Jun 23].

Padron-Regalado E. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect Dis Ther 2020;9:255-74.

COVID-19 Will Mutate-what That Means for a Vaccine. Available from: https://www.healthline.com/health-news/what-to-know-about-mutation-and-covid-19#What-this-means-for-a-vaccine. [Last accessed on 2020 Jun 23].

What Is a Coronavirus Vaccine? Available from: https://www.sciencealert.com/coronavirus-vaccine. [Last accessed on 2020 Jun 23].

Favipiravir for Coronavirus Treatment: Check how Glenmark’s Covid-19 Medicine FabiFlu Works-the Financial Express. Available from: https://www.financialexpress.com/lifestyle/health/favipiravir-for-coronavirus-treatment-check-how-glenmars-covid-19-medicine-fabiflu-works/1999512. [Last accessed on 2020 Jun 25].

Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies: Introduction, Investigational Antiviral Agents, Immunomodulators and Other Investigational Therapies. Available from: https://www.emedicine.medscape.com/article/2500116-overview#a2. [Last accessed on 2020 Jun 23].

The Phases of Preclinical and Clinical Trials. Available from: https://www.profil.com/knowledge-center/trial-stages. [Last accessed on 2020 Jun 25].

Clinical Trial Phases: What Happens in Phase 0, I, II, III, and IV. Available from: https://www.healthline.com/health/clinical-trial-phases#phase-i. [Last accessed 2020 Jun 25].

What is a Phase 3 Clinical Trial? Available from: https://www.news-medical.net/health/What-is-a-Phase-3-Clinical-Trial.aspx. [Last accessed on 2020 Jun 25].

Coronavirus, Covid-19 Vaccine India Latest News Update: How Close Are we to a Covid-19 Vaccine, What is the Testing Process? Available form: https://www.indianexpress.com/article/explained/how-close-are-we-to-coronavirus-covid-19-vaccine-what-is-the-testing-process-6471283. [Last accessed on 2020 Jun 25].

What is Favipiravir? How Does It Work for COVID-19? Huateng Pharma Pharmaceutical Chemical Reagents, PEG Derivatives. Available from: https://www.en.huatengsci.com/article/140.html. [Last accessed on 2020 Jun 25].

Available from: https://www.scientificupdate.com/wp-content/uploads/2020/04/Picture2.png. [Last accessed on 2020 Jun 25].

Favipiravir-drugbank. Available from: https://www.drugbank.ca/drugs/DB12466. [Last accessed on 2020 Jun 27].

Glenmark Says FabiFlu Reduces Viral Load by 4 Days, Treats Mild to Moderate COVID-19. Business News-India TV. Available from: https://www.indiatvnews.com/business/news-fabiflu-tablets-dosage-covid-19-treatment-favipiravir-glenmark-indian-company-gets-approval-628184. [Last accessed on 2020 Jun 27].

Favipiravir Observational Study Group. Preliminary Report of the Favipiravir Observational Study in Japan. China: Favipiravir Observational Study Group; 2020.

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection-du--clinical Pharmacology Therapeutics-Wiley Online Library. Available from: https://www.ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1844. [Last accessed on 2020 Jun 27].

IrieK, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, et al. Pharmacokinetics of favipiravir in critically ill patients with COVID‐19. Clin Transl Sci 2020;13:880-5.

Favipiravir DrugBank. Available from: https://www.drugbank.ca/drugs/DB12466#BE0009866. [Last accessed on 2020 Jun 28].

Favipiravir C5H4FN3O2. Available from: https://www.pubchem.ncbi.nlm.nih.gov/compound/492405#section=Metabolism-Metabolites. [Last accessed on 2020 Jun 28].

Avigan 英文仿單. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw. [Last accessed on 2020 Jun 28].

Reaction: Favipiravir to 1 Product DrugBank. Available from: https://www.drugbank.ca/reactions/5550. [Last accessed on 2020 Jun 28].

Favipiravir-drugs and Lactation Database (LactMed). Available from:https://www.ncbi.nlm.nih.gov/books/NBK556878. [Last accessed on 2020 Jun 28].

Favipiravir (T-705)≥99%(HPLC) Selleck DNA/RNA Synthesis Inhibitor. Available from: https://www.selleckchem.com/products/favipiravir-t-705.html. [Last accessed on 2020 Sep 08].

Clinical Study to Evaluate the Performance and Safety of Favipiravir in COVID-19-tabular View. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT04336904?term=favipiravir&cond=Covid-19&draw=2&rank=1. [Last accessed on 2020 Jun 28].

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating Favipiravir in Treatment of COVID19-tabular. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT04425460?term=favipiravir&cond=Covid-19&draw=2. [Last accessed on 2020 Jun 28].

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19-tabular View. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT04358549?term=favipiravir&cond=Covid19&draw=2. [Last accessed on 2020 Jun 29].

Efficacy and Safety of Favipiravir in Management of COVID-19-tabular View. Available fom: https://www.clinicaltrials.gov/ct2/show/record/NCT04349241?term=favipiravir&cond=Covid19&draw=2.[Last accessed on 2020 Jun 29].

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19-tabular View. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT04346628?term=favipiravir&cond=Covid19&draw=2. [Last accessed on 2020 Jun 29].

Takahashi H, Iwasaki Y, Watanabe T, Ichinose N, Okada Y, Oiwa A, et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis 2020;100:283-5.

Fusion Health Care Launches Favipiravir for COVID-19 Treatment. Available from: https://www.expresspharma.in/covid19-updates/fusion-health-care-launches-favipiravir-for-covid-19-treatment. [Last accessed on 2020 Sep 08].

Murohashi K, Hagiwara E, Kitayama T, Yamaya T, Higa K, Sato Y, et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respir Investig 2020;

Glenmark to Study Potential COVID-19 Drug Combination on Favipiravir, Umifenovir in India. Available from: https://www.oneindia.com/india/glenmark-to-study-potential-covid-19-drug-combination-on-favipiravir-umifenovir-in-india-3094526.html. [Last accessed on 2020 Sep 08].